+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Bivalirudin Market by Dosage Form, Application, End-Use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967607
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Bivalirudin Market grew from USD 1.23 billion in 2023 to USD 1.31 billion in 2024. It is expected to continue growing at a CAGR of 6.13%, reaching USD 1.87 billion by 2030.

Bivalirudin is an anticoagulant specifically aimed at treating patients with unstable angina undergoing percutaneous coronary intervention (PCI) and is used as an alternative to heparin. Its necessity is underscored by its effectiveness in reducing bleeding complications relative to its predecessor, thus fulfilling critical clinical needs, particularly for patients sensitive to heparin or those requiring anticoagulation management during PCI. The application extends to its potential use across various surgical and interventional arenas where anticoagulation is paramount. The end-use scope largely involves hospitals, clinics, and specialized cardiac centers where procedural anticoagulation is required. Key growth factors in the bivalirudin market include the rising prevalence of cardiovascular diseases, advancements in medical techniques, and an increasing number of surgical procedures globally. There are burgeoning opportunities in expanding its use in broader surgical procedures beyond cardiac interventions, particularly in regions with rising healthcare expenditures like Asia-Pacific. However, challenges such as high cost of bivalirudin compared to traditional anticoagulants and potential competition from novel anticoagulants could potentially hinder market growth. Moreover, stringent regulatory approvals and varying healthcare guidelines can also act as a deterrent. Opportunities for innovation include developing more cost-effective formulations and enhancing delivery mechanisms, such as extended-release variants, to improve patient compliance. In addition, conducting extensive clinical trials to explore newer therapeutic indications could provide a competitive edge. The market is competitive yet fragmented, with numerous players vying for innovation leadership. Companies that can streamline production efficiencies and align with evolving healthcare policies stand best poised to capitalize on growth opportunities. It is essential for businesses to focus on strategic partnerships and collaborations with cardiac and surgical centers to enhance product visibility and penetration, thus catering effectively to the evolving needs of healthcare professionals and patients alike.

Understanding Market Dynamics in the Bivalirudin Market

The Bivalirudin Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing need for effective anticoagulants to treat cardiovascular disorders
    • Growing consumer expenditure for improved drug and medications
  • Market Restraints
    • Expensive nature of bivalirudin compared to the alternatives
  • Market Opportunities
    • Emerging development of ready-to-use bivalirudin formulations
    • Ongoing government approvals for new products
  • Market Challenges
    • Risks and complexities associated with use of bivalirudin

Exploring Porter’s Five Forces for the Bivalirudin Market

Porter’s Five Forces framework further strengthens the insights of the Bivalirudin Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Bivalirudin Market

External macro-environmental factors deeply influence the performance of the Bivalirudin Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Bivalirudin Market

The Bivalirudin Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Bivalirudin Market

The Bivalirudin Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Bivalirudin Market

The Bivalirudin Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bivalirudin Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma, Avenacy, Inc., Baxter International, Cayman Chemical, Cipla Limited, Dr. Reddy’s Laboratories, Endo International plc, Eugia US LLC, Fresenius Kabi, Meitheal Pharmaceuticals, Inc., Merck KGaA, Midas Pharma GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bivalirudin Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Dosage Form
    • Injection
    • Powder
  • Application
    • Angioplasty
    • Heparin-induced Thrombocytopenia
    • Percutaneous Coronary Intervention
  • End-Use
    • Ambulatory Surgical Centers
    • Hospitals & Clinics
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing need for effective anticoagulants to treat cardiovascular disorders
5.1.1.2. Growing consumer expenditure for improved drug and medications
5.1.2. Restraints
5.1.2.1. Expensive nature of bivalirudin compared to the alternatives
5.1.3. Opportunities
5.1.3.1. Emerging development of ready-to-use bivalirudin formulations
5.1.3.2. Ongoing government approvals for new products
5.1.4. Challenges
5.1.4.1. Risks and complexities associated with use of bivalirudin
5.2. Market Segmentation Analysis
5.2.1. Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures
5.2.2. End-Use: Emerging usage of bivalirudin in ambulatory surgical centers
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bivalirudin Market, by Dosage Form
6.1. Introduction
6.2. Injection
6.3. Powder
7. Bivalirudin Market, by Application
7.1. Introduction
7.2. Angioplasty
7.3. Heparin-induced Thrombocytopenia
7.4. Percutaneous Coronary Intervention
8. Bivalirudin Market, by End-Use
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals & Clinics
8.4. Specialty Clinics
9. Americas Bivalirudin Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Bivalirudin Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Bivalirudin Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Avenacy Introduces Generic Bivalirudin Injection, Expanding Anticoagulant Options in the U.S.
12.3.2. Endo International Launches Ready-to-Use Bivalirudin Injection Enhancing Clinical Efficiency
12.3.3. Endo International Announces Strategic Partnership for U.S. Distribution of Ready-to-Use Bivalirudin Injection
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BIVALIRUDIN MARKET RESEARCH PROCESS
FIGURE 2. BIVALIRUDIN MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIVALIRUDIN MARKET DYNAMICS
TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 28. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 29. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 32. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 45. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 46. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 48. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 49. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 55. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 73. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 83. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 86. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 89. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 92. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 95. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 100. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 101. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 110. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 112. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 113. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 115. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 116. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 128. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 137. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 145. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Bivalirudin Market, which are profiled in this report, include:
  • Apotex Inc.
  • Aurobindo Pharma
  • Avenacy, Inc.
  • Baxter International
  • Cayman Chemical
  • Cipla Limited
  • Dr. Reddy’s Laboratories
  • Endo International plc
  • Eugia US LLC
  • Fresenius Kabi
  • Meitheal Pharmaceuticals, Inc.
  • Merck KGaA
  • Midas Pharma GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information